Abstract
The ubiquitin system of protein modification has emerged as a crucial mechanism involved in the regulation of a wide array of cellular processes. As our knowledge of the pathways in this system has grown, so have the ties between the protein ubiquitin and human disease. The power of the ubiquitin system for therapeutic benefit blossomed with the approval of the proteasome inhibitor Velcade in 2003 by the FDA. Current drug discovery activities in the ubiquitin system seek to (i) expand the development of new proteasome inhibitors with distinct mechanisms of action and improved bioavailability, and (ii) validate new targets. This review summarizes our current understanding of the role of the ubiquitin system in various human diseases ranging from cancer, viral infection and neurodegenerative disorders to muscle wasting, diabetes and inflammation. I provide an introduction to the ubiquitin system, highlight some emerging relationships between the ubiquitin system and disease, and discuss current and future efforts to harness aspects of this potentially powerful system for improving human health.Republished from Current BioData's Targeted Proteins database (TPdb; ).
Highlights
Overview of the ubiquitin system The ubiquitin system is a hierarchical enzymatic cascade in which a ubiquitin-activating enzyme (E1) activates the 76 amino acid protein UBIQ in an ATPdependent manner and transfers it to the active site cysteine of ubiquitin-conjugating enzymes (E2s) [1]
UBIQ chains using a lysine residue of one UBIQ molecule attached via an isopeptide bond to the C-terminus of another UBIQ molecule add further complexity to UBIQ-encoded protein fate
I describe some relationships between the ubiquitin system and various human diseases
Summary
Overview of the ubiquitin system The ubiquitin system is a hierarchical enzymatic cascade in which a ubiquitin-activating enzyme (E1) activates the 76 amino acid protein UBIQ (ubiquitin) in an ATPdependent manner and transfers it to the active site cysteine of ubiquitin-conjugating enzymes (E2s) [1]. The stability of P53 (p53) is regulated by ubiquitin ligases and a deubiquitylating enzyme (DUB) The transcription factor P53 has a crucial role in cellular anticancer mechanisms and it has been estimated that >50% of tumors contain mutations in the P53 gene [37].
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have